Actively Recruiting
Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Led by Domain Therapeutics Australia Pty Ltd · Updated on 2026-05-06
125
Participants Needed
9
Research Sites
131 weeks
Total Duration
On this page
Sponsors
D
Domain Therapeutics Australia Pty Ltd
Lead Sponsor
D
Domain Therapeutics SA
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a phase 1/2, dose-escalation, clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of DT-7012 (an anti-CCR8 monoclonal antibody) as a single agent and in combination with an immune checkpoint inhibitor in adult participants with selected advanced solid tumors.
CONDITIONS
Official Title
Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed solid tumor, among selected cancer types, that is recurrent, locally advanced (not eligible for curative surgery or radiotherapy) or metastatic, has progressed after at least one line of systemic therapy and has no established curative option
- Measurable disease per RECIST v1.1 as assessed by the local site investigator or radiologist
- At least 1 tumor lesion accessible to biopsy per treating physician judgment
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function
You will not qualify if you...
- Any unresolved adverse events from previous anti-cancer therapies of grade 2 or higher, except alopecia
- Prior severe immune-related adverse events leading to immunotherapy treatment discontinuation
- Major surgery or significant traumatic injury within 4 weeks before Cycle 1 Day 1 without adequate recovery
- Prior radiotherapy within 4 weeks before Cycle 1 Day 1 or limited field palliative radiotherapy within 2 weeks before Cycle 1 Day 1
- Prior anti-CCR8 monoclonal antibody treatment received in an investigational trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Honor Health Research Institute
Scottsdale, Arizona, United States, 85258
Not Yet Recruiting
2
Macquarie University Clinical Trial Unit
North Ryde, New South Wales, Australia, 2109
Actively Recruiting
3
Cancer Research SA
Adelaide, South Australia, Australia, 5000
Actively Recruiting
4
Peninsula & South Eastern Haematology & Oncology Group
Frankston, Victoria, Australia, 3199
Actively Recruiting
5
Cabrini Health Limited
Malvern, Victoria, Australia, 3144
Actively Recruiting
6
One Clinical Research Pty Ltd
Nedlands, Western Australia, Australia, 6009
Actively Recruiting
7
Institut Bergonié
Bordeaux, France, 33076
Actively Recruiting
8
Hôpitaux Universitaires de Strasbourg
Strasbourg, France, 67200
Actively Recruiting
9
Institut Gustave Roussy
Villejuif, France, 94800
Actively Recruiting
Research Team
C
Clinical Development
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here